May 22, 2017
PHILADELPHIA — Patients treated with bempedoic acid in addition to high-intensity statin therapy had a reduction in LDL, according to results presented in a late-breaker session at the National Lipid Association Scientific Sessions.
“Bempedoic acid, or ETC-1002, is a pro-drug, and it needs to be converted into its active form by a very specific Acyl-CoA synthetase that is ... found in the liver and to a much lesser extent in the kidneys, but certainly not in the muscle cell,” Mary McGowan, MD, chief medical officer at Esperion Therapeutics and director of the Lipid Clinic at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, said in the presentation. “By [converting] ETC-1002, you get ETC-1002 CoA, and this is an inhibitor of ATP citrate lyase. ATP citrate lyase is an enzyme upstream from the HMG-CoA reductase enzyme, and as such, inhibition here does exactly what statins do.”